Stay updated on Pembrolizumab/Vibostolimab Combo in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab/Vibostolimab Combo in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab/Vibostolimab Combo in NSCLC Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    Change Detected
    Summary
    Revision label updated from v3.3.1 to v3.3.2 in the page footer. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-11-28T01:30:55.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    Page revision updated from v3.2.0 to v3.3.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-11-20T22:36:54.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    Added a new trial site: Tainan, Taiwan, 704, and removed the Tainan City, Taiwan, 704 listing; a government funding status notice was also deleted.
    Difference
    0.2%
    Check dated 2025-11-13T17:08:27.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    No substantive changes to the core study content were detected; observed differences are limited to layout or metadata changes. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2025-10-30T11:32:08.000Z thumbnail image
  7. Check
    75 days ago
    Change Detected
    Summary
    Page updated to Revision: v3.2.0 from Revision: v3.0.2; indicates a new release version with no other substantive content changes.
    Difference
    0.0%
    Check dated 2025-10-01T05:35:37.000Z thumbnail image
  8. Check
    82 days ago
    Change Detected
    Summary
    - The page has removed key drug-safety topics (MedlinePlus Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs), signaling a shift away from detailed drug-safety content.
    Difference
    0.3%
    Check dated 2025-09-24T01:06:29.000Z thumbnail image

Stay in the know with updates to Pembrolizumab/Vibostolimab Combo in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab/Vibostolimab Combo in NSCLC Clinical Trial page.